Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer

被引:6
作者
Minagawa, Y
Kigawa, J
Kanamori, Y
Itamochi, H
Terakawa, N
Okada, M
Kitada, F
机构
[1] Tottori Prefectural Cent Hosp, Dept Obstet & Gynecol, Tottori 6800901, Japan
[2] Yamaguchi Red Cross Hosp, Dept Obstet & Gynecol, Yamaguchi, Japan
[3] Osaka Saiseikai Suita Hosp, Dept Obstet & Gynecol, Suita, Osaka, Japan
关键词
ovarian cancer chemotherapy docetaxel cisplatin; carboplatin;
D O I
10.1016/j.ygyno.2005.11.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To determine the feasibility of docetaxel-cisplatin combination therapy compared with docetaxel-carboplatin combination therapy as first-line chemotherapy for patients with ovarian cancer. Methods. Fifty patients with International Federation of Gynecology and Obstetrics stage Ic-IV ovarian cancer who underwent primary surges,. were randomly assigned to receive treatment with docetaxel-cisplatin (n = 23) or docetaxel-carboplatin (n = 27). Docetaxel 70 mg/m(2) and cisplatin 60 mg/m(2) or carboplatin to an area under the curve of 5 were administered consecutively on Day 1 of a 3-week cycle, for 3 cycles in patients with stage Ic-II cancer and for over 5 cycles in patients with stage III-IV cancer. Patients were evaluated for treatment-related toxicity in each cycle using the National Cancer Institute Common Toxicity Criteria version 2.0. Results. Five patients (2 in the docetaxel-cisplatin arm and 3 in the docetaxel-carboplatin ann) discontinued the treatment at the end of the second course of chemotherapy because of apparent disease progression; however, no patients came off the protocol therapy because of treatment-related toxicity. Overall. 103 cycles of docetaxel-cisplatin treatment and 130 cycles of docetaxel-carboplatin treatment were delivered. The major toxicity was neutropenia in both regimens. The total incidence of grades 3 and 4 neutropenia was 83% (19/23) in the docetaxel-cisplatin arm and 96% (26/27) in the docetaxel-carboplatin arm. The incidence of grade 4 neutropenia was significantly lower in the docetaxel-cisplatin ann [39% (9/23) versus 74% (20/27)]. Conclusion. Docetaxel-cisplatin combination therapy may be feasible as first-line chemotherapy for patients with ovarian cancer. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:495 / 498
页数:4
相关论文
共 50 条
[31]   Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer [J].
Takahide Arimoto ;
Shunsuke Nakagawa ;
Katsutoshi Oda ;
Kei Kawana ;
Toshiharu Yasugi ;
Yuji Taketani .
Medical Oncology, 2012, 29 :1253-1254
[32]   First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients [J].
Romanini, A ;
Tanganelli, L ;
Carnino, F ;
Fanucchi, A ;
Lionetto, R ;
Pastorino, S ;
Cosio, S ;
Gadducci, A ;
Conte, PF .
GYNECOLOGIC ONCOLOGY, 2003, 89 (03) :354-359
[33]   A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population [J].
Merry, Eve ;
Kesmez, Ronas Taner ;
Yu, Tamara ;
Flynn, Michael ;
Ledermann, Jonathan ;
Lockley, Michelle ;
Macdonald, Nicola ;
Mccormack, Mary ;
Nicum, Shibani ;
Crusz, Shanthini ;
Miller, Rowan .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024,
[34]   A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer [J].
Harries, M ;
Moss, C ;
Perren, T ;
Gore, M ;
Hall, G ;
Everard, M ;
A'Hern, R ;
Gibbens, I ;
Jenkins, A ;
Shah, R ;
Cole, C ;
Pizzada, O ;
Kaye, S .
BRITISH JOURNAL OF CANCER, 2004, 91 (04) :627-632
[35]   A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer [J].
M Harries ;
C Moss ;
T Perren ;
M Gore ;
G Hall ;
M Everard ;
R A'Hern ;
I Gibbens ;
A Jenkins ;
R Shah ;
C Cole ;
O Pizzada ;
S Kaye .
British Journal of Cancer, 2004, 91 :627-632
[36]   Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: A phase II study [J].
Jahanzeb, M ;
Sarna, G ;
Hirsch, R ;
Radice, P ;
Koletsky, A ;
Martinez, M ;
Kruglyak, E ;
Wolin, E ;
Camacho, E ;
Kronish, L ;
Motl, S .
ANTICANCER RESEARCH, 2004, 24 (2C) :1239-1242
[37]   Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer [J].
duBois, A ;
Luck, HJ ;
Bauknecht, T ;
Mobus, V ;
Bochtler, H ;
Diergarten, K ;
Meerpohl, HG .
ANNALS OF ONCOLOGY, 1997, 8 (04) :355-361
[38]   Paclitaxel, carboplatin, and hexamethylmelamine (taxchex) as first-line therapy for ovarian cancer [J].
Hartenbach, EM ;
Harris, LS ;
Bailey, HH ;
Grosen, EA ;
Larrison, E ;
Chen, D ;
Twiggs, LB ;
Schink, JC .
CANCER JOURNAL, 1999, 5 (06) :348-355
[39]   A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer [J].
V J O'Neill ;
S B Kaye ;
N S Reed ;
J Paul ;
J A Davis ;
P A Vasey .
British Journal of Cancer, 2002, 86 :1385-1390
[40]   Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study [J].
Nagao, S ;
Fujiwara, K ;
Oda, T ;
Ishikawa, H ;
Koike, H ;
Tanaka, H ;
Kohno, I .
GYNECOLOGIC ONCOLOGY, 2005, 96 (03) :805-809